Using cold to enhance immune therapy for breast cancer
Cold-responsive gene and drug delivery-potentiated cryoimmunotherapy
['FUNDING_R01'] · UNIV OF MARYLAND, COLLEGE PARK · NIH-11002337
This study is exploring a new way to treat breast cancer by using freezing to shrink tumors and boost the body's immune system to fight the cancer better, and it's aimed at people looking for less invasive treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF MARYLAND, COLLEGE PARK (nih funded) |
| Locations | 1 site (COLLEGE PARK, UNITED STATES) |
| Trial ID | NIH-11002337 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating breast cancer by combining cryotherapy, which involves freezing tumors, with immunotherapy to improve the immune response against cancer. The goal is to create a more favorable tumor microenvironment that allows immune cells to better infiltrate and attack the cancer cells. By temporarily freezing the tumor, the researchers aim to induce cell death and stimulate an immune response that can help combat metastasis. This method is designed to be minimally invasive, offering a potential alternative to traditional surgical methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with breast cancer, especially those experiencing metastasis.
Not a fit: Patients with non-breast cancer types or those who are not eligible for cryotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for breast cancer, particularly in cases where the cancer has spread.
How similar studies have performed: Previous research has shown promise in using cryotherapy to enhance immune responses in cancer treatment, indicating that this approach may be effective.
Where this research is happening
COLLEGE PARK, UNITED STATES
- UNIV OF MARYLAND, COLLEGE PARK — COLLEGE PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HE, XIAOMING — UNIV OF MARYLAND, COLLEGE PARK
- Study coordinator: HE, XIAOMING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy